Diabetic Gastroparesis - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 63
Price : Single User: US $ 2000  US $ 1700 Corporate User: US $ 6000  US $ 4800
Inquire Before Buying
This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Diabetic Gastroparesis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Diabetic Gastroparesis - Pipeline Review, H2 2016', provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis

- The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects

- The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Diabetic Gastroparesis - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Gastroparesis Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Gastroparesis - Overview 8
Pipeline Products for Diabetic Gastroparesis - Comparative Analysis 9
Diabetic Gastroparesis - Therapeutics under Development by Companies 10
Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes 11
Diabetic Gastroparesis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Diabetic Gastroparesis - Products under Development by Companies 15
Diabetic Gastroparesis - Products under Investigation by Universities/Institutes 16
Diabetic Gastroparesis - Companies Involved in Therapeutics Development 17
Cempra Inc 17
Evoke Pharma, Inc. 18
GlaxoSmithKline Plc 19
Motus Therapeutics Inc 20
Shire Plc 21
Theravance Biopharma, Inc. 22
Diabetic Gastroparesis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
camicinal - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CEM-031 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ETX-101 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ETX-301 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
metoclopramide hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
prucalopride succinate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
relamorelin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
velusetrag hydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Diabetic Gastroparesis - Dormant Projects 52
Diabetic Gastroparesis - Discontinued Products 53
Diabetic Gastroparesis - Product Development Milestones 54
Featured News & Press Releases 54
Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 54
Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial 54
Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement 55
Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 55
May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 56
May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 56
May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 57
Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 57
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 58
Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 58
Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 59
Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 59
Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 60
Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 60
Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables
Number of Products under Development for Diabetic Gastroparesis, H2 2016 8
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2016 17
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2016 18
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2016 19
Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H2 2016 20
Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2016 21
Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Diabetic Gastroparesis - Dormant Projects, H2 2016 52
Diabetic Gastroparesis - Discontinued Products, H2 2016 53

List of Figures
Number of Products under Development for Diabetic Gastroparesis, H2 2016 8
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Targets, H2 2016 24
Number of Products by Mechanism of Actions, H2 2016 26
Number of Products by Stage and Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30
  • Global Anti Peptic Ulcer Drugs Market Research Report 2017
    Published: 17-Aug-2017        Price: US 2900 Onwards        Pages: 116
    In this report, the global Anti Peptic Ulcer Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Anti Peptic Ulcer Drugs in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Diarrhea Drug Sales Market Report 2017
    Published: 16-Aug-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Diarrhea Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Diarrhea Drug for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan -......
  • Global Diarrhea Drug Market Research Report 2017
    Published: 09-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Diarrhea Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Diarrhea Drug in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global and United States Digestive system agents In-Depth Research Report 2017-2022
    Published: 04-Aug-2017        Price: US 3190 Onwards        Pages: 126
    The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2016 to 2022. This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Digestive system agents industry. Major Companies - Sigma-Tau Industrie Farmaceutiche Riunite S.p.A......
  • Global Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 2500 Onwards        Pages: 113
    Key Findings Global Opioid Induced Constipation (OIC) drug market is estimated to grow at a CAGR of 4.88% during the forecast period of 2017 - 2025. The major drivers responsible for the market growth are: • Rising use of opioid • Increasing geriatric population • Increasing opioid prescription in North America and Europe • Detection of safety threats • Easy availability of improved and effective OIC drugs Some of the commonly prescribed opioids ......
  • Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 54
    Key Findings The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market. Market Insights The Asian market can be classified on the basis of drug type and prescription type. Th......
  • Europe opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 52
    Key Findings The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period of 2017-2025. The market value is predicted to increase from $896.3 million in 2016 and reach up to $1273.34 million by 2025. Market Insights The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs s......
  • North America Opioid Induced Constipation Drug Market Forecast 2017-2025
    Published: 01-Aug-2017        Price: US 1250 Onwards        Pages: 51
    Key Findings The North America opioid induced constipation drug market is expected to be the fastest growing market during the forecast period of 2017-2025 with an expected CAGR growth of 5.72%. The revenue generated by the market is expected to increase from $840.4 million in 2016 and reach $1382.73 million by 2025. Market Insights The North American OIC drug market is segmented on the basis of the type of prescription and the type of drug. The prescription type market is f......
  • Global Digestive system agents Detailed Analysis Report 2017-2022
    Published: 31-Jul-2017        Price: US 3250 Onwards        Pages: 125
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Digestive system agents industry. This report splits Digestive system agents market by Promoting ingestion drugs, by Antispasmodic and gastro-kinetic agent, by Cathartic and antidiarrheal drugs, by Others, which covers the history data information fr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs